Prilosec OTC impacting Protonix?
This article was originally published in The Tan Sheet
Wyeth reiterates Procter & Gamble's recent launch of Prilosec OTC (omeprazole) will not impact sales of its Rx GERD treatment Protonix (pantoprazole sodium) (1"The Tan Sheet" July 28, 2003, p. 11). During Bear Stearns Healthcare Conference in New York City Sept. 9, Wyeth North America President Joseph Mahady notes "the change in market status from a single omeprazole generic to now having multiple generics...will more than likely have the most significant change on the market. In our opinion that will be more critical to the performance of Protonix in the future than will be the availability of an OTC version of Prilosec"...
You may also be interested in...
Wyeth is confident that its Alavert loratadine product will weather the launch of several private label and generic rivals and build on the brand's strong second quarter sales performance
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.